-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
AG 555
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/133550-34-2.gif)
| Category | Influenza Virus |
| CAS | 133550-34-2 |
| Description | AG 555 is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (IC50 = 0.7 μM) with 50-fold and >140-fold selectivity over ErbB2 and insulin receptor kinase respectively. |
Product Information
| Synonyms | AG 555; AG-555; AG555; (E)-2-cyano-3-(3,4-dihydroxyphenyl)-N-(3-phenylpropyl)prop-2-enamide; AG 555; AG-555; alpha-cyano-(3,4-dihydroxy)-N-(3-phenylpropyl)cinnamide; N-(3'-Phenylpropyl)-3,4-dihydroxybenzylidenecyanoacetamide; N-(3-phenylpropyl)-3,4-dihydroxybenzylidene cyanoacetamide; tyrphostin AG 555; tyrphostin AG-555; tyrphostin B46 |
| IUPAC Name | (E)-2-cyano-3-(3,4-dihydroxyphenyl)-N-(3-phenylpropyl)prop-2-enamide |
| Molecular Weight | 322.36 |
| Molecular Formula | C19H18N2O3 |
| Canonical SMILES | C1=CC=C(C=C1)CCCNC(=O)C(=CC2=CC(=C(C=C2)O)O)C#N |
| InChI | 1S/C19H18N2O3/c20-13-16(11-15-8-9-17(22)18(23)12-15)19(24)21-10-4-7-14-5-2-1-3-6-14/h1-3,5-6,8-9,11-12,22-23H,4,7,10H2,(H,21,24)/b16-11+ |
| InChIKey | GSQOBTOAOGXIFL-LFIBNONCSA-N |
| Boiling Point | 621.1±55.0 ℃ at 760 Torr |
| Flash Point | 329.4±31.5 °C |
| Purity | ≥98% (HPLC) |
| Density | 1.273±0.06 g/cm3 |
| Solubility | DMSO |
| Appearance | Light yellow to yellow (Solid) |
| Storage | Store in a cool and dry place (or refer to the Certificate of Analysis). |
| Complexity | 488 |
| Exact Mass | 322.131744 |
| Index Of Refraction | 1.650 |
| In Vitro | AG 555 inhibits both the early stages (integration process) and the late stages (viral protein synthesis) in the virus life cycle. Tyrphostins AG555, which blocks Cdk2 activation, induces growth arrest of immortalized cells at G1-S and early S and is very effective in arresting the growth of EGFR overexpressor cells. Tyrphostin AG 555 can selectively suppress BPV-1 transcription through MAP kinase pathway activation and binding of phosphorylated JuTF-2 at a novel intragenic regulatory sequence. |
| Target | EGFR; Reverse Transcriptase |
| Vapor Pressure | 0.0±1.9 mmHg at 25°C |
| XLogP3-AA | 3.2 |
